The expression and significance of MiRNA-107 in acute myeloid leukemia

Objective: To explore the expression and significance of miRNA-107 in acute myeloid leukemia. Methods: Real-time quantitative PCR (qRT-PCR) was used to detect 100 cases of bone marrow mononuclear cells from patients with primary acute myeloid leukemia (the observation group) and non-hematologic tumor disease (the control group) who underwent bone marrow puncture at the same time. With this, the expression level of cellular miRNA-107 were measured in both groups. The direct sequencing method was used to detect IDHl, IDH2, NPML, FLT3-ITD, DNMT3 A and CEBPα mutations. The predictive efficacy of miRNA-107 on the risk of acute myeloid leukemia was analyzed using receiver operating curve (ROC). 100 patients were also divided into the high miRNA-107 expression group (50 cases) and low miRNA-107 expression group (50 cases) according to the median expression level of miRNA-107. The relationships between miRNA-107 expression and clinical indexes, gene mutations and prognosis were analyzed in both groups. Results: The level of miRNA-107 in the observation group was significantly lower than that of the control group (P < 0.05), and the area under the ROC curve of miRNA-107 for predicting the risk of acute myeloid leukemia was 0.877. The HGB level, proportion of NPM1 wild type and complete remission rate in the high miRNA-107 expression group were significantly higher than those of the low miRNA-107 expression group (P < 0.05). There were no significant differences in gender, age, WBC, PLT, bone marrow blast cell ratio, CEBPα, FLT3-ITD, IDH1/2 and DNMT3 A between the two groups (P > 0.05). The median overall survival (OS) time and median recurrence-free survival (RFS) time which were 26 months and 21.5 months in the high miRNA-107 expression group were significantly higher than those of the low miRNA-107 expression group which were 15 months and 11.8 months (P < 0.05). Multivariate analysis using Cox regression model showed that low miRNA-107 expression was an independent risk factor for poor prognosis in patients with acute myeloid leukemia (P < 0.05). Conclusion: High expression of miRNA-107 is a good prognostic marker for patients with acute myeloid leukemia. miRNA-107 can be used as an indicator to predict the risk of acute myeloid leukemia, and can also be used as an important indicator to evaluate the prognosis of patients with acute myeloid leukemia. (authors)